Dr. Peter N. Mattar, MD
Family Medicine (Family Medicine Physician)
9961 Sierra Ave
Fontana, CA 92335
Who else practices at this address →
San Bernardino County includes primary care (5% of residents) and mental health (26% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Loma Linda University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 96
Licensed in California since 2006, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Loma Linda University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
CA license A97235 (first issued 2006; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Citrus Valley Medical Associates Inc (14 clinicians)
- Platinum Providers Medical Group Inc (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 96
- Services billed
- 207
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 119 | 71 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 43 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 17 payments worth $393 in total to this clinician.
| Lilly USA, LLC | $103 |
|---|---|
| Novo Nordisk Inc | $72.30 |
| Dexcom, Inc. | $62.64 |
| GlaxoSmithKline, LLC. | $49.91 |
| AbbVie Inc. | $43.52 |
| Astellas Pharma US Inc | $24.72 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.38 |
| AstraZeneca Pharmaceuticals LP | $16.76 |
| Food and Beverage | $393 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $340,973 in research payments for these studies, mostly to the institutions running them.
- PREPARE PuraPly AM/XT
Organogenesis Inc. - A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company · Completed · NCT06045221 - A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company · Completed · NCT05971940 - A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - 20 VLU 003 AFF study
Organogenesis Inc. - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.